MM
Model Medicines
United States · Biotech
Model Medicines uses AI to discover and develop small molecule drug candidates targeting biological mechanisms shared across diseases.
Product and customers
Model Medicines develops small molecule drug candidates using an AI platform that supports target discovery, molecular design and preclinical development. Its approach focuses on biological mechanisms that can affect multiple diseases.
Its research programmes include antiviral therapies targeting viral RNA polymerase and therapies targeting the BRD4 transcriptional regulator. The San Diego biotechnology company is advancing investigational compounds through preclinical development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity offering | $5.1M | Participants not disclosed |